Management of branch retinal vein occlusion

British Journal of Hospital Medicine

Volumn 73, Issue 1, 2012, Pages 20-23

  Shirodkhar, Amy Lee ^a   Lightman, Sue ^b   Taylor, Simon R J ^c  

^a Clinical Ophthalmology ^*

^b National Institute of Health Research   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855999376     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2012.73.1.20     Document Type: Conference Paper

References (31)

1. Appiah AP, Trempe CL (1989) Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophthalmol 21(4): 153-5, 7
2. Aras S, Yilmaz G, Alpas I, Baltaci V, Tayanc E, Aydin P (2001) Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. Eur J Ophthalmol 11(4): 351-5 (Pubitemid 34160713)
3. Campochiaro PA, Hafiz G, Shah SM et al (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16(4): 791-9 (Pubitemid 351426182)
4. Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six- Month Primary End Point Results of a Phase III Study. Ophthalmology 117(6): 1102-12 e1
5. Cekic O, Chang S, Tseng JJ et al (2005) Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 25(7): 851-5 (Pubitemid 41456575)
6. Chen SD, Sundaram V, Lochhead J, Patel CK (2006) Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141(5): 876-83
7. Cheung N, Klein R, Wang JJ et al (2008) Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 49(10): 4297-302
8. Di Capua M, Coppola A, Albisinni R et al (2009) Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 30(1): 16-22
9. Dodson PM, Clough CG, Downes SM, Kritzinger EE (1993) Does type II diabetes predispose to retinal vein occlusion? Eur J Ophthalmol 3(3): 109-13 (Pubitemid 23325840)
10. Domalpally A, Blodi BA, Scott IU et al (2009) The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4. Arch Ophthalmol 127(11): 1461-7
11. Haller JA, Bandello F, Belfort R Jr et al (2010) Randomized, Shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6): 1134-46.e3
12. Hamid S, Mirza SA, Shokh I (2008) Anatomic pattern of arteriovenous crossings in branch retinal vein occlusion. J Pak Med Assoc 58(5): 233-6 (Pubitemid 351769465)
13. Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) [OCTguided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion]. Ophthalmologe 105(12): 1121-6
14. Kaneda S, Miyazaki D, Sasaki S et al (2011) Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci 52(6): 2982-8
15. Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126(4): 513-18 (Pubitemid 351549845)
16. Kuhli-Hattenbach C, Scharrer I, Luchtenberg M, Hattenbach LO (2009) [Selective thrombophilia screening of young patients with retinal vein occlusion]. Klin Monbl Augenheilkd 226(9): 768-73
17. Kuhli-Hattenbach C, Scharrer I, Luchtenberg M, Hattenbach LO (2010) Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 103(2): 299-305
18. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL (1998) The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 105(3): 424-7 (Pubitemid 28125094)
19. McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5): 835-54
20. Martin SC, Butcher A, Martin N et al (2002) Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 86(7): 774-6 (Pubitemid 34713165)
21. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20): 1897-908
22. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114(10): 1243-7 (Pubitemid 26338856)
23. National Institute for Health and Clinical Excellence (2011) Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. National Institute for health and Clinical Excellence, London (http://guidance.nice.org. uk/nicemedia/live/13037/54692/ 54692.pdf accessed 1 December 2011)
24. Noma H, Funatsu H, Sakata K, Harino S, Mimura T, Hori S (2009) Macular microcirculation in hypertensive patients with and without branch retinal vein occlusion. Acta Ophthalmol 87(6): 638-42
25. Oh J, Oh IK, Huh K (2007) Diurnal variation of the incidence of symptomatic branch retinal vein occlusion. Ophthalmologica 221(4): 251-4 (Pubitemid 46956803)
26. Rogers SL, McIntosh RL, Lim L et al (2010) Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6): 1094-101.e5
27. Rosenfeld PJ (2011) Bevacizumab versus ranibizumab for AMD. N Engl J Med 364(20): 1966-7
28. Royal College of Ophthalmologists (2009) Retinal Vein Occlusion Interim Guidelines. www.rcophth.ac.uk/core/core-picker/ download.asp?id=337 (accessed 12 December 2011)
29. Scott IU, Ip MS, VanVeldhuisen PC et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127(9): 1115-28
30. Simons BD, Brucker AJ (1997) Branch retinal vein occlusion. Axial length and other risk factors. Retina 17(3): 191-5 (Pubitemid 27265731)
31. Sperduto RD, Hiller R, Chew E et al (1998) Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 105(5): 765-71